
Head of Product Marketing (Remote US)
Legion Intelligence
USA (Remote)
USA (Remote)
Posted 2 weeks ago
The other 99% submit and hope. You're about to do something different.
Own the HCP brand strategy and execution for the US launch, drive segmentation and go-to-market plans, and lead compliant promotional campaigns end-to-end.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVATM (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVATM (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVATM (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD, expected in the second quarter of calendar 2025. In the United States, ONS-5010/LYTENAVATM is investigational, and a BLA has been resubmitted to the FDA in the United States. If approved in the United States, ONS-5010/LYTENAVATM, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.

Legion Intelligence
USA (Remote)

LVT
American Fork, UT (Remote)
The Nielsen Company
USA (Remote)

Boulevard
USA (Remote)

Boulevard
USA (Remote)
12+ roles like Senior Director - HCP Marketing at Outlook Therapeutics, Inc.
See more similar roles and save the ones you want to track.